Form 4: NextCure Insider Sells Shares
Insider Transaction (Form 4)
Simcere Zaiming, Inc. and 5 others reported changes in beneficial ownership of NextCure, Inc. common stock on August 10, 2026.
Summary
- Open-market sale: disposed of 30,000 Common Stock at $6.16 ($184,800) on August 10, 2026; holds 308,636 after (Indirect).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $184,800 of stock on the open market.
Insider Transactions
Simcere Zaiming, Inc. — Other (Former 10% Owner)
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. — Other (Former 10% Owner)
Simcere Zaiming Pharmaceutical Co., Ltd. — Other (Former 10% Owner)
Simcere Pharmaceutical Group Ltd — Other (Former 10% Owner)
Jinsheng Ren — Other (Former 10% Owner)
Renhong Tang — Other (Former 10% Owner)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Open-market sale | Common Stock | 30,000 | $6 | $184.8K | 308,636 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Open-market sale (30,000 shares) |
Keywords
insider transaction, Form 4, NXTC, NextCure, Inc., bearish, Simcere Zaiming, Inc., Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Zaiming Pharmaceutical Co., Ltd., Simcere Pharmaceutical Group Ltd, Jinsheng Ren, Renhong Tang
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.